Botulinum Toxin A to Treat Arm Tremor

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

PROPECTIVE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF NT 201 IN THE UNILATERAL TREATMENT OF ESSENTIAL TREMOR OF THE UPPER LIMB

Intervention/treatment:
NT 201 (XEOMIN)
Medical condition:
LIMB SPASTICITY
Protocol code:
MRZ60201_2094_1
Control number:
174118
Status:
Closed
Approved:
May 23, 2014
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT02207946
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Public Disclosure Manager
Organization
Merz Pharmaceuticals GmbH
Phone:
+49 69 1503 1
Sponsor
MERZ PHARMACEUTICALS GMBH

Locations

Manitoba

Merz Investigational Site #0010317
Winnipeg, Manitoba, R3J2H7

Nova Scotia

Merz Investigational Site #0010089
Halifax, Nova Scotia, B3P 1M3

Ontario

Merz Investigational Site #0010078
Toronto, Ontario, M5T 2S8
Merz Investigational Site #0010305/1
Toronto, Ontario, M6M 2J5
Merz Investigational Site #0010305/2
Toronto, Ontario, M6M 2J5

Results

See the results from the trial NCT02207946. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?